Probiotics as an alternative to eliminate Pseudomonas aeruginosa biofilm
Özet
Pseudomonas aeruginosa is a clinically important opportunistic pathogen characterized by high antibiotic resistance and strong biofilm-forming capacity, posing a major therapeutic challenge, particularly in immunocompromised patients. In this study, we aimed to evaluate the antibiotic resistance profiles and biofilm-forming abilities of clinical isolates, and to investigate the antibiofilm potential of the probiotic strain Lacticaseibacillus rhamnosus. A total of 66 clinical isolates were analyzed, revealing high levels of antibiotic resistance, while 87.9% of isolates demonstrated biofilm-forming capacity. Treatment with L. rhamnosus at 25% and 50% concentrations resulted in significant antimicrobial and antibiofilm effects. MIC and antibiofilm assays indicated that these effects were dose- and cell density-dependent. Scanning electron microscopy analyses confirmed the structural disruption of biofilms following treatment. Furthermore, real-time PCR results demonstrated that the expression levels of key biofilm-associated genes (algD, pelF, pslD, ppgl, and PAPI-1) were reduced by more than 50%. Importantly, this study provides evidence that L. rhamnosus can effectively inhibit both biofilm formation and biofilm-associated gene expression in multidrug-resistant P. aeruginosa isolates, highlighting its potential as a promising alternative or adjunctive biocontrol strategy against biofilm-related infections. These findings contribute to the growing body of research on probiotic-based approaches targeting antimicrobial resistance and biofilm-associated pathogenicity. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2026.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Celebi, Selahattin | |
| dc.contributor.author | Celebi, Ozgur | |
| dc.contributor.author | Celebi, Demet | |
| dc.contributor.author | Baser, Sumeyye | |
| dc.contributor.author | Dabanlioglu, Bulent | |
| dc.contributor.author | Ektas Kalayci, Sila | |
| dc.contributor.author | Aslan, Sumeyye | |
| dc.contributor.author | Islamoglu, Fatma | |
| dc.contributor.author | Taghizadehghalehjoughi, Ali | |
| dc.date.accessioned | 2026-10-18T20:25:22.601382035Z | |
| dc.date.available | 2026-10-18T20:25:22.601382035Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Pseudomonas aeruginosa is a clinically important opportunistic pathogen characterized by high antibiotic resistance and strong biofilm-forming capacity, posing a major therapeutic challenge, particularly in immunocompromised patients. In this study, we aimed to evaluate the antibiotic resistance profiles and biofilm-forming abilities of clinical isolates, and to investigate the antibiofilm potential of the probiotic strain Lacticaseibacillus rhamnosus. A total of 66 clinical isolates were analyzed, revealing high levels of antibiotic resistance, while 87.9% of isolates demonstrated biofilm-forming capacity. Treatment with L. rhamnosus at 25% and 50% concentrations resulted in significant antimicrobial and antibiofilm effects. MIC and antibiofilm assays indicated that these effects were dose- and cell density-dependent. Scanning electron microscopy analyses confirmed the structural disruption of biofilms following treatment. Furthermore, real-time PCR results demonstrated that the expression levels of key biofilm-associated genes (algD, pelF, pslD, ppgl, and PAPI-1) were reduced by more than 50%. Importantly, this study provides evidence that L. rhamnosus can effectively inhibit both biofilm formation and biofilm-associated gene expression in multidrug-resistant P. aeruginosa isolates, highlighting its potential as a promising alternative or adjunctive biocontrol strategy against biofilm-related infections. These findings contribute to the growing body of research on probiotic-based approaches targeting antimicrobial resistance and biofilm-associated pathogenicity. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2026. | |
| dc.description.sponsorship | This study was supported by Erzincan Binali Y\u0131ld\u0131r\u0131m University Scientific Research Projects Coordination with project number TCD-2023\u2013916. | |
| dc.identifier.doi | 10.1007/s10482-026-02391-x | |
| dc.identifier.eissn | 1572-9699 | |
| dc.identifier.issn | 0003-6072 | |
| dc.identifier.issue | 8 | |
| dc.identifier.pmcid | 10681627 | |
| dc.identifier.pmid | 42496927 | |
| dc.identifier.scopus | 2-s2.0-105045501898 | |
| dc.identifier.startpage | 173 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/10122 | |
| dc.identifier.volume | 119 | |
| dc.identifier.wos | WOS:001829589400001 | |
| dc.language.iso | en | |
| dc.publisher | Springer Science and Business Media Deutschland GmbH | |
| dc.relation.ispartof | Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Antibiotic resistance | |
| dc.subject | Biofilm | |
| dc.subject | Lacticaseibacillus rhamnosus | |
| dc.subject | Pseudomonas aeruginosa | |
| dc.subject | Anti-Bacterial Agents | |
| dc.subject | Biofilms | |
| dc.subject | Drug Resistance, Bacterial | |
| dc.subject | Humans | |
| dc.subject | Microbial Sensitivity Tests | |
| dc.subject | Probiotics | |
| dc.subject | Pseudomonas Infections | |
| dc.subject | amikacin | |
| dc.subject | ampicillin | |
| dc.subject | avibactam plus ceftazidime | |
| dc.subject | aztreonam | |
| dc.subject | cefepime | |
| dc.subject | ceftazidime | |
| dc.subject | ceftriaxone | |
| dc.subject | cefuroxime | |
| dc.subject | cefuroxime axetil | |
| dc.subject | ciprofloxacin | |
| dc.subject | cotrimoxazole | |
| dc.subject | imipenem | |
| dc.subject | meropenem | |
| dc.subject | piperacillin plus tazobactam | |
| dc.subject | probiotic agent | |
| dc.subject | tigecycline | |
| dc.subject | antiinfective agent | |
| dc.subject | algD gene | |
| dc.subject | antibiofilm activity | |
| dc.title | Probiotics as an alternative to eliminate Pseudomonas aeruginosa biofilm | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 0 | |
| rdl.citation.wos | 0 | |
| rdl.department | Faculty of Medicine Department of Medical Microbiology, Erzincan Binali Yıldırım University, 24002, Erzincan, Turkey. | Faculty of Pharmacy Department of Pharmaceutical Microbiology, Erzincan Binali Yıldırım University, 24002, Erzincan, Turkey. | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
